Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
ADC Therapeutics (ADCT) Stock Price & Analysis
248 Followers
ADCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $6.04
Previous Close$4.72
Volume646.03K
Average Volume (3M)748.97K
Market Cap
$390.88M
Enterprise Value$367.39M
Total Cash (Recent Filing)$31.15M
Total Debt (Recent Filing)$7.66M
Price to Earnings (P/E)-1.6
Beta1.89
Next Earnings
May 07, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.93
Shares Outstanding82,529,549
10 Day Avg. Volume474,939
30 Day Avg. Volume748,970
Standard Deviation0.29
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-4.45
Price to Sales (P/S)1.86
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.62
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$10.20Price Target Upside116.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
ADC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementThe LOTIS-7 trial progresses with no dose-limiting toxicities and anti-tumor activity observed, supporting the continued development of the treatment.
Drug Development ProgressPreclinical data for GB01-VA-PL2202 and NaPi2b-PL2202 show promising cell binding and cytotoxicity, hinting at their potential for clinical success.
Market Growth PotentialZYNLONTA, the company's commercial drug, is on a growth trajectory with expansion in academic and community settings, signaling increasing market penetration.
Bears Say
Clinical Trial ResultsStock suffered due to the announcement of a higher-than-expected censoring rate in the LOTIS-5 study.
Drug DevelopmentADC's discontinuation of its KAAG1-targeted ADC reflects limited efficacy in the Phase 1 trial, marking a negative turn in the drug's development.
Product PipelineThe company faces a potential loss in momentum as the KAAG1-targeted ADC program is halted after disappointing Phase 1 trial results.
---
Ownership Overview
0.00%
Insiders
10.61% Mutual Funds
0.23% Other Institutional Investors
89.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.36 and its highest was $6.04 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
Currently, no data Available
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is May 07, 2024 which is in 14 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Mar 13, 2024. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.502 by -$0.528.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -$0.56.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 82,814,000 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.502. Following the earnings report the stock price went down -12.36%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Among the largest hedge funds holding ADC Therapeutics Ltd’s share is Grosvenor Holdings, L.L.C.. It holds ADC Therapeutics Ltd’s shares valued at 3M.
---
ADC Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.20 (116.10% Upside)
$10.20 (116.10% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.95%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
---
ADCT Company Deck
---
ADCT Earnings Call
Q4 2024
0:00 / 0:00
---
ADCT Stock 12 Months Forecast
Average Price Target
$10.20
▲(116.10% Upside)
Technical Analysis
Best Analysts Covering ADCT
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+84.63%
reiterated a buy rating 20 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +84.63% per trade.
---